Article
Oncology
Xiaozhen Zhang, Mengyi Lao, Jian Xu, Yi Duan, Hanshen Yang, Muchun Li, Honggang Ying, Lihong He, Kang Sun, Chengxiang Guo, Wen Chen, Haitao Jiang, Xiaoyu Zhang, Xueli Bai, Tingbo Liang
Summary: Combination therapy with anti-TNFR2 and anti-PD-L1 can eradicate tumors, prolong overall survival, and activate robust antitumor immune response in advanced pancreatic ductal adenocarcinoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Qiang Chen, Shuqing Zhuang, Yilin Hong, Lingtao Yang, Peng Guo, Pingli Mo, Kesong Peng, Wengang Li, Nengming Xiao, Chundong Yu
Summary: The study found that PD-L1 and JMJD2D are frequently overexpressed in human CRC specimens and have a significant positive correlation. Knocking out JMJD2D in CRC cells weakens the expression of PD-L1, inhibits tumor growth, and increases the number and function of CD8(+) T cells in tumor infiltration. JMJD2D promotes the expression of PD-L1 by co-activating SP-1 to promote the expression of IFNGR1, thereby enhancing STAT3-IRF1 signaling. Pharmacological inhibition of JMJD2D can improve the therapeutic effect of PD-L1 antibody, increase the infiltration and function of CD8(+) T cells.
Article
Oncology
Ganggang Zhang, Bin Lan, Xin Zhang, Mengyao Lin, Yi Liu, Junsong Chen, Fang Guo
Summary: PD-1 and its ligand PD-L1 protect tumor cells from T cell-mediated killing. Understanding the regulatory mechanisms of PD-L1 expression can help develop more effective therapeutic strategies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Ying Qi, Xiaoming Huang, Chunxia Ji, Chaojun Wang, Yu Yao
Summary: This article reviews the unsatisfactory results of PD-1/PD-L1 inhibitors in high grade glioma treatment, and discusses the current status of predictive biomarkers and emerging strategies, as well as the clinical significance and therapeutic strategies of the immune checkpoint B7-H4 in pre-clinical glioma models.
TRANSLATIONAL ONCOLOGY
(2024)
Review
Oncology
Valentin Vautrot, Hafidha Bentayeb, Sebastien Causse, Carmen Garrido, Jessica Gobbo
Summary: Immunotherapy, particularly through the blockade of immune checkpoints such as PD-1/PD-L1, has become increasingly important in cancer treatment by reactivating the immune system to fight cancer cells. However, resistance to these treatments in a certain proportion of patients has led to efforts to combine PD-1/PD-L1 immunotherapy with targeting other immune checkpoints to improve outcomes. Exosomes, small vesicles secreted by various cells including tumor cells, play a key role in mediating immune resistance and establishing metastatic niches. Research on specific exosomal proteins like PD-L1, CTLA-4, TIM-3, CD73/39, LAG-3, and TIGIT aims to enhance understanding of tumor resistance mechanisms and guide therapeutic decisions in immunotherapy.
Review
Oncology
Laure Chardin, Alexandra Leary
Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a high recurrence rate, despite many patients responding effectively to current treatments. In order to improve outcomes, further research into the immune microenvironment and the development of effective therapies are urgently needed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Chao Yu, Xinyi Zhang, Min Wang, Gaoxin Xu, Siqi Zhao, Yongheng Feng, Chao Pan, Weijun Yang, Jin Zhou, Longcheng Shang, Yong Ma
Summary: Afatinib has a significant inhibitory effect on liver cancer cells and can suppress their growth, invasion, and migration. It enhances the expression of PD-L1 in tumor cells through the STAT3/PD-L1 pathway. The combination of afatinib and anti-PD1 treatment significantly increases the immunotherapeutic effect of hepatocellular carcinoma.
FRONTIERS IN ONCOLOGY
(2023)
Editorial Material
Oncology
Michael R. Pitter, Weiping Zou
Summary: The article demonstrates that immune checkpoint blockade can enhance the response of tumor-specific T cells against tumor cells, effectively increasing tumor cell lysis, and provides scientific rationale for a new generation of cancer treatment targeting the PD-1/PD-L1 signaling pathway in the tumor microenvironment.
Review
Oncology
Meng-ke Fan, Li-li Qi, Qi Zhang, Ling Wang
Summary: The article reviews the expression, function, and regulatory mechanism of the B7-H1/PD-1 axis in osteosarcoma, and introduces and compares the advantages and disadvantages of B7-H1/PD-1 immunotherapies in osteosarcoma.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Holly K. Koblish, Liangxing Wu, Liang-Chuan S. Wang, Phillip C. C. Liu, Richard Wynn, Jonathan Rios-Doria, Susan Spitz, Hao Liu, Alla Volgina, Nina Zolotarjova, Kanishk Kapilashrami, Elham Behshad, Maryanne Covington, Yan-Ou Yang, Jingwei Li, Sharon Diamond, Maxim Soloviev, Kevin O'Hayer, Stephen Rubin, Chrysi Kanellopoulou, Gengjie Yang, Mark Rupar, Darlise DiMatteo, Luping Lin, Christina Stevens, Yue Zhang, Pramod Thekkat, Ryan Geschwindt, Cindy Marando, Swamy Yeleswaram, Jeff Jackson, Peggy Scherle, Reid Huber, Wenqing Yao, Gregory Hollis
Summary: This study describes the identification and characterization of a novel oral small-molecule PD-L1 inhibitor, INCB086550. It shows that INCB086550 can selectively and potently block PD-L1/PD-1 interaction, induce PD-L1 dimerization and internalization, and stimulate cytokine production in human immune cells. In animal models and preliminary clinical data, INCB086550 demonstrates tumor growth reduction and increased immune activation, supporting its potential as an alternative therapy to antibody-based treatments.
Article
Biochemistry & Molecular Biology
Dorota Suszczyk, Wiktoria Skiba, Witold Zardzewialy, Anna Pawlowska, Karolina Wlodarczyk, Grzegorz Polak, Rafal Tarkowski, Iwona Wertel
Summary: This study found that the PD-L1/PD-L2 pathway plays an important role in EMS. In the peritoneal fluid of EMS patients, there is an increased proportion of mDCs and pDCs expressing PD-L1 or PD-L2, as well as a higher concentration of soluble PD-L1 and PD-L2. This suggests that the peritoneal cavity environment and the PD-1/PD-L1/PD-L2 axis may play a crucial role in regulating immune response and the development and/or progression of EMS.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Zheng-Zheng Yu, Yun-Ya Liu, Wei Zhu, Ding Xiao, Wei Huang, Shan-Shan Lu, Hong Yi, Ting Zeng, Xue-Ping Feng, Li Yuan, Jie-Ya Qiu, Di Wu, Qi Wen, Jian-Hua Zhou, Wei Zhuang, Zhi-Qiang Xiao
Summary: The study focuses on the role and mechanism of A11 in degrading PD-L1 and its effect on tumor immune evasion. A11 competes with USP7 to degrade PD-L1 and exhibits significant antitumor effects. A11 also shows synergistic antitumor activity with PD-1 mAb.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biology
Tomohiro Takehara, Ei Wakamatsu, Hiroaki Machiyama, Wataru Nishi, Katsura Emoto, Miyuki Azuma, Kenzo Soejima, Koichi Fukunaga, Tadashi Yokosuka
Summary: PD-1 forms microclusters with PD-L1/2 to inhibit T cell activation, with PD-L2 competing with PD-L1 for binding to PD-1. The cluster formation affects T cell signaling and serves as a visual index for the effectiveness of PD-1/2 inhibitory therapy.
COMMUNICATIONS BIOLOGY
(2021)
Review
Chemistry, Multidisciplinary
Qian Wu, Li Jiang, Si-cheng Li, Qiao-jun He, Bo Yang, Ji Cao
Summary: PD-1/PD-L1 signaling pathway is a target for anticancer drugs, and the development of small molecule inhibitors provides a new avenue for tumor immunotherapy.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Oncology
Alexandr Bazhin, Katharina von Ahn, Jasmin Fritz, Henriette Bunge, Caroline Maier, Orkhan Isayev, Florian Neff, Jens T. Siveke, Svetlana Karakhanova
Summary: B7-H1 molecule has the potential to control the immunosuppressive network in PDAC. Inhibiting B7-H1 expression can reduce tumor volume, improve survival rate of PDAC patients, and restore anti-tumor immune response.